Ibrutinib for Schnitzler syndrome with concurrent hematologic malignancy
Jani P, et al.
J Oncol Pract 14(6):387-388 · 2018
Abstract
[Abstract not available]
Key Findings
- ●First report of ibrutinib for Schnitzler syndrome
- ●Concurrent hematologic malignancy
Subject Classification
AdenineAged, 80 and overExanthemaHistocytochemistryHumansMalePiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesSchnitzler SyndromeSkinTreatment Outcome
Referenced in (1 disease)
Validation history
Full log →No validation events recorded yet. Source will be checked on the next kipine-source-validator run.
ID: pmid-29558252DOI: 10.1200/JOP.18.00091PMID: 29558252PMCID: PMC7846060